Apalutamide

27 trials 9 recruiting LOncology

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

9 Recruiting

16 Completed trials

19 Sponsors

20 Countries

Phase III

Phase II

Phase III: 17 Phase II: 8 Phase I/II: 1 Phase I (FiH): 1

Oversight events:

6 unexpected events across 2 trials

View oversight register →

Indications tested

Prostate cancer metastatic 6 Prostate cancer 3 Prostate cancer recurrent 1

Sponsors using this IMP

Janssen - Cilag International 6 Novartis Pharma AG 3 Region Vaesterbotten 2 Unicancer 2 Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard 1 Aragon Pharmaceuticals Inc. 1 AstraZeneca AB 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 European Organisation For Research And Treatment Of Cancer 1 Fondazione Radioterapia Oncologica Onlus 1 HUS-Yhtymae 1 Karolinska Institutet 1

All trials — page 2

27 total

An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended

2023-508606-26-00 Phase III 3 countries Janssen Cilag International
A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res… Ended

2023-509221-47-00 Phase III 12 countries Aragon Pharmaceuticals Inc.
Inducta Ended

2023-509837-37-00 Phase II 1 country Universitaet Des Saarlandes

Showing 25–27 of 27 trials

← All drugs A–Z